Nurix Therapeutics price target raised to $34 from $32 at Truist
Truist analyst Gregory Renza raised the firm's price target on Nurix Therapeutics to $34 from $32 and keeps a Buy rating on the shares after its Q2 results. The company's earnings and the firm's follow-up call with the management were focused on the recent Roche (RHHBY) partnership, which further broadens the path to v